{"entity":{"id":"nct04042831","kind":"trial","name":"Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations","aka":[],"tldr":"A phase 2 trial of olaparib in gallbladder cancer and other biliary tract cancers, run by Academic and Community Cancer Research United, active and no longer recruiting.","summary":"Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations is a phase 2 interventional study registered as NCT04042831 by Academic and Community Cancer Research United, with a registry enrolment figure of 32 participants, started 2020-06-24 and due to reach its primary completion in 2025-03-12. Interventions recorded: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib. Conditions listed: Bile Duct Adenocarcinoma, Fanconi Anemia Complementation Group Gene Mutation, Metastatic Bile Duct Carcinoma, PTEN Gene Deletion. Sites: United States. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.","status":"active","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT04042831","url":"https://clinicaltrials.gov/study/NCT04042831"}],"tags":["ctgov-ingest","gallbladder-deep-dive"],"related":[],"cancers":["gallbladder","cholangiocarcinoma","biliary-tract-cancer"],"sections":[],"technologies":["parp-inhibitor"],"targets":[],"drugs":["olaparib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04042831","phase":"2","setting":"A Phase II Study of Olaparib in Patients With Advanced Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations","sponsor":"Academic and Community Cancer Research United","yearReported":2026,"enrolled":32,"enrolledBasis":"registry","outcomes":[{"endpoint":"Number of Patients Alive and Progression-free at First Scan","primary":true,"unit":"participants","arms":[{"name":"Treatment (Olaparib)","n":31,"value":23,"note":"Figures from the ClinicalTrials.gov results section (first posted 2026-05-15), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT04042831?tab=results"},{"endpoint":"Overall Survival (OS)","unit":"months","arms":[{"name":"Treatment (Olaparib)","n":31,"value":11,"note":"95% CI 8.8 to 28.8; Figures from the ClinicalTrials.gov results section (first posted 2026-05-15), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT04042831?tab=results"},{"endpoint":"Progression-free Survival (PFS)","unit":"weeks","arms":[{"name":"Treatment (Olaparib)","n":31,"value":16.9,"note":"95% CI 14.0 to 24.7; Figures from the ClinicalTrials.gov results section (first posted 2026-05-15), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT04042831?tab=results"}]},"route":"/trials/nct04042831/","neighbours":{"cancer":[{"id":"biliary-tract-cancer","kind":"cancer","name":"Biliary tract cancer (all types)","route":"/cancers/biliary-tract-cancer/"},{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/"}],"technology":[{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"}],"drug":[{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"}],"term":[{"id":"gallbladder-cancer-in-biliary-trials","kind":"term","name":"Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)","route":"/terms/gallbladder-cancer-in-biliary-trials/"}]}}